Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

it's about as confident tone as you can expect from or as you'd want from a management team," said Kevin Gade, chief operating officer at Bahl & Gaynor, which owns Lilly's shares. Eli Lilly also ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...